|Bid||15.70 x 100|
|Ask||17.26 x 500|
|Day's range||16.19 - 16.91|
|52-week range||8.71 - 27.09|
|PE ratio (TTM)||N/A|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||37.17|
Omeros shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 85.
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Omeros Corporation today announced that it has reached agreement with the US Food and Drug Administration on Omeros’ protocol for its Phase 3 clinical trial evaluating OMS721 in patients with IgA nephropathy .
Omeros (OMER) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Omeros Corporation , a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced that the U.S.
Omeros rocketed to a month-high Friday after revenue from eye-surgery drug Omidria beat its typical summertime weakness.
Omeros Corp. shares rose 17% in premarket trade Friday after the company reported a third-quarter revenue beat and a narrower-than-expected profit loss. The company reported a loss of $7.48 million, or ...
On a per-share basis, the Seattle-based company said it had a loss of 16 cents. Losses, adjusted for non-recurring costs, came to 7 cents per share. The drug developer posted revenue of $21.7 million in ...
Omeros Corporation , a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for
Omeros Corporation today announced that extended follow-up data from patients with immunoglobulin A nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology Meeting in New Orleans.
Omeros Corporation , today announced that the company will issue its third quarter 2017 financial results for the period ended September 30, 2017, on Thursday, November 9, 2017, after the market closes.
Omeros Corporation today announced that a subset of data will be presented from the company’s Phase 2 clinical trial of OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 , for the treatment of glomerulonephropathies.
Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.
Omeros Corporation today announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy and graft-versus-host disease , which both resolved following OMS721 treatment.
Omeros Corporation today announced that data will be presented from the company’s Phase 2 clinical trial of OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 , for the treatment of thrombotic microangiopathies .
Omeros Corporation today announced that it entered into a settlement agreement with Par Pharmaceutical, Inc. and its subsidiary Par Sterile Products, LLC , resolving Omeros’ patent litigation against Par.
Omeros Corporation (NASDAQ: OMER) today announced that data from the company’s Phase 2 clinical trial of OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy and other kidney diseases will be presented at the 54th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Madrid, Spain. The poster “The Effect of OMS721 on Proteinuria in Patients with IgA Nephropathy,” scheduled for presentation on Sunday, June 4, 2017, describes data from the trial’s IgA nephropathy cohort. Geoffrey Block, M.D., Director of Clinical Research at Denver Nephrology and Principal Investigator of the Phase 2 trial, will discuss the data.